$1.14/ day, billed weekly
Cancel anytime

(Ads Free, Unlimited access)

NO CREDIT CARD REQUIRED

First Wave BioPharma Inc (FWBI)FWBI

First Wave BioPharma Inc

$2.98

Delayed price

PASS

BUY Advisory
Profitable SELL
Loss-Inducing SELL

Profit
Loss
PASS (Skip invest)*

Time period over

ALL
YEAR
MONTH
WEEK

Time period over

Upturn Advisory Summary

05/17/2024: FWBI (1-star) is currently NOT-A-BUY. Pass it for now.

Analysis of Past Performance

Type: Stock	Upturn Star Rating	Today’s Advisory: PASS
Historic Profit: -9.6%	Upturn Advisory Performance 1	Avg. Invested days: 13
Profits based on simulation	Stock Returns Performance 1	Last Close 05/17/2024

Type: Stock	Today’s Advisory: PASS
Historic Profit: -9.6%	Avg. Invested days: 13
Upturn Star Rating	Stock Returns Performance 1
Profits based on simulation Last Close 05/17/2024	Upturn Advisory Performance 1

Key Highlights

Company Size Small-Cap Stock	Market Capitalization 5.99M USD
Price to earnings Ratio -	1Y Target Price 36
Dividends yield (FY) -	Basic EPS (TTM) -47.88
Volume (30-day avg) 44009	Beta 1.28
52 Weeks Range 2.33 - 37.40	Updated Date 06/16/2024

Company Size Small-Cap Stock	Market Capitalization 5.99M USD	Price to earnings Ratio -	1Y Target Price 36
Dividends yield (FY) -	Basic EPS (TTM) -47.88	Volume (30-day avg) 44009	Beta 1.28
52 Weeks Range 2.33 - 37.40	Updated Date 06/16/2024

Earnings Date

Report Date -	When -
Estimate -	Actual -

Report Date -

When -

Estimate -

Actual -

Profitability

Profit Margin -

Operating Margin (TTM) -

Management Effectiveness

Return on Assets (TTM) -27.07%

Return on Equity (TTM) -15.28%

Valuation

Trailing PE -	Forward PE -
Enterprise Value 72608424	Price to Sales(TTM) -
Enterprise Value to Revenue -	Enterprise Value to EBITDA -0.24
Shares Outstanding 2025200	Shares Floating 2335544
Percent Insiders 5.66	Percent Institutions 1.46

Trailing PE -	Forward PE -	Enterprise Value 72608424	Price to Sales(TTM) -
Enterprise Value to Revenue -	Enterprise Value to EBITDA -0.24	Shares Outstanding 2025200	Shares Floating 2335544
Percent Insiders 5.66	Percent Institutions 1.46

Analyst Ratings

Rating 3.5	Target Price 11	Buy 1
Strong Buy -	Hold 1	Sell -
Strong Sell -

Rating 3.5	Target Price 11	Buy 1	Strong Buy -
Hold 1	Sell -	Strong Sell -

About First Wave BioPharma Inc

Exchange	NASDAQ	Headquaters	Boca Raton, FL, United States
IPO Launch date	2016-10-11	CEO & Chairman	Mr. James R. Sapirstein M.B.A., R.Ph.
Sector	Healthcare	Website	https://www.firstwavebio.com
Industry	Biotechnology	Full time employees	9
Headquaters	Boca Raton, FL, United States
CEO & Chairman	Mr. James R. Sapirstein M.B.A., R.Ph.
Website	https://www.firstwavebio.com
Website	https://www.firstwavebio.com
Full time employees	9

First Wave BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the research and development of targeted and non-systemic therapies for the treatment of patients with gastrointestinal diseases. Its product candidates include latiglutenase, a targeted oral biotherapeutic for celiac disease designed to breakdown gluten into non-immunogenic peptides; biologic adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients; capeserod, a selective 5-HT4 receptor partial agonist to treat gastroparesis; and niclosamide, an oral small molecule with anti-inflammatory properties for patients with inflammatory bowel diseases, such as ulcerative colitis and Crohn's disease. It is also developing CypCel, a disease management tool for monitoring the intestinal health of recovering celiac disease patients. The company was formerly known as AzurRx BioPharma, Inc. and changed its name to First Wave BioPharma, Inc. in September 2021. First Wave BioPharma, Inc. was incorporated in 2014 and is headquartered in Boca Raton, Florida.

https://www.upturn.io

Disclosure Privacy Policy Terms of Use Sitemap Contact Us

Upturn is now on iOS and Android!

Experience Upturn on your mobile. Install it now!

Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.